OP43L
Anti-p53 (Ab-6) (Pantropic) Mouse mAb (DO-1)
lyophilized, clone DO-1, Calbiochem®
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Code UNSPSC :
12352203
Produits recommandés
Source biologique
mouse
Niveau de qualité
Forme d'anticorps
purified antibody
Type de produit anticorps
primary antibodies
Clone
DO-1, monoclonal
Forme
lyophilized
Ne contient pas
preservative
Espèces réactives
feline, human
Ne doit pas réagir avec
mouse, rat
Fabricant/nom de marque
Calbiochem®
Conditions de stockage
OK to freeze
Isotype
IgG2a
Conditions d'expédition
ambient
Température de stockage
2-8°C
Modification post-traductionnelle de la cible
unmodified
Informations sur le gène
human ... TP53(7157)
Description générale
Purified mouse monoclonal antibody generated by immunizing BALB/c mice with the specified immunogen and fusing splenocytes with X63Ag8.653 mouse myeloma cells (see application references). Recognizes the ~53 kDa mutant and wild-type forms of p53.
Recognizes the ~53 kDa wild-type and mutant p53 protein in A431 cells and breast carcinoma tissue.
This Anti-p53 (Ab-6) (Pantropic) Mouse mAb (DO-1) is validated for use in Frozen sections, Gel Shift, Immunoblotting, ICC, IP, Paraffin sections for the detection of p53 (Ab-6) (Pantropic).
Immunogène
Epitope: Within amino acids 21-25 of human p53
Human
wild type, recombinant, human p53
Application
Frozen sections (1 µg/ml; see application references)
Gel Shift (see comments)
Immunoblotting (0.1 µg/ml; see application references)
Immunocytochemistry (1-2.5 µg/ml; see application references)
Immunoprecipitation (1 µg/ml or use Cat. No. OP43A; see application references)
Paraffin sections (1 µg/ml, pepsin, heat or pressure cooker pre-treatment required; see application references)
Gel Shift (see comments)
Immunoblotting (0.1 µg/ml; see application references)
Immunocytochemistry (1-2.5 µg/ml; see application references)
Immunoprecipitation (1 µg/ml or use Cat. No. OP43A; see application references)
Paraffin sections (1 µg/ml, pepsin, heat or pressure cooker pre-treatment required; see application references)
Avertissement
Toxicity: Standard Handling (A)
Forme physique
Lyophilized from a volatile buffer, 100 µg BSA.
Reconstitution
We recommend resuspending the lyophilized antibody with sterile phosphate buffered saline (PBS), pH 7.4, or sterile 20 mM Tris-saline (20 mM Tris containing 0.15 M NaCl), pH 7.4, to yield a final concentration of 100 μg/ml. Reconstituted product will be more stable if 0.1% sodium azide is added (do not add azide if antibody is to be used with viable cells). Lyophilized antibodies should be resuspended at 4°C with occasional gentle mixing for at least two hours. Following reconstitution, refrigerate (4°C) for short-term storage or aliquot and freeze (-20°C) for long-term storage.
Remarque sur l'analyse
Negative Control
SK-OV-3 cells or normal skin tissue
SK-OV-3 cells or normal skin tissue
Positive Control
A431 cells or breast carcinoma tissue
A431 cells or breast carcinoma tissue
Autres remarques
El-Deiry, W.S., et al. 1994. Cancer Res.54, 1169.
Greenblatt, M.S., et al. 1994. Cancer Res.54, 4855.
Legros, Y., et al. 1994. Oncogene9, 2071.
Barak, Y., et al. 1993. EMBO J.12, 461.
Kastan, M.B., et al. 1992. Cell71, 587.
Kuerbitz, S.J. 1992. Proc. Natl. Acad. Sci. USA89, 7491.
Lane, D.P. 1992. Nature358, 15.
Vojtesek, B., et al. 1992. J. Immunol. Meth.151, 237.
Kastan, M.B., et al. 1991 Cancer Res.51, 6304.
Greenblatt, M.S., et al. 1994. Cancer Res.54, 4855.
Legros, Y., et al. 1994. Oncogene9, 2071.
Barak, Y., et al. 1993. EMBO J.12, 461.
Kastan, M.B., et al. 1992. Cell71, 587.
Kuerbitz, S.J. 1992. Proc. Natl. Acad. Sci. USA89, 7491.
Lane, D.P. 1992. Nature358, 15.
Vojtesek, B., et al. 1992. J. Immunol. Meth.151, 237.
Kastan, M.B., et al. 1991 Cancer Res.51, 6304.
Recognizes both mutant and wild-type p53 under denaturing and non-denaturing conditions. This antibody reacts weakly with rodent p53; we do not recommend it for rodent samples. For gel shift assay, resuspend in 100 µl of buffer. Wild-type p53 has a short half life and is present in low amounts in cells. For immunoprecipitation increasing the amount of sample and labeling with 35S-Met for less than or equal to 1 h will aid in visualizing wild-type p53. Antibody should be titrated for optimal results in individual systems.
Informations légales
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Vous ne trouvez pas le bon produit ?
Essayez notre Outil de sélection de produits.
Code de la classe de stockage
11 - Combustible Solids
Classe de danger pour l'eau (WGK)
WGK 3
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Darren M Hutt et al.
Methods in molecular biology (Clifton, N.J.), 1510, 77-91 (2016-10-21)
Gene expression is regulated in part through the reversible acetylation of histones, by the action of histone acetyltransferases (HAT) and histone deacetylases (HDAC). HAT activity results in the addition of acetyl groups on the lysine residues of histone tails leading
E E Hoskins et al.
Oncogene, 27(35), 4798-4808 (2008-04-29)
Fanconi anemia (FA) is a genome instability syndrome that is characterized by progressive bone marrow failure and a high risk of cancer. FA patients are particularly susceptible to leukemia as well as squamous cell carcinomas (SCCs) of the head and
Yan Degenhardt et al.
Molecular cancer therapeutics, 9(7), 2079-2089 (2010-06-24)
Polo-like kinases are a family of serine threonine kinases that are critical regulators of cell cycle progression and DNA damage response. Predictive biomarkers for the Plk1-selective inhibitor GSK461364A were identified by comparing the genomics and genetics of a panel of
H Takahashi et al.
Oncogene, 36(30), 4267-4276 (2017-03-28)
L-asparaginase has been used for more than three decades in acute lymphoblastic leukemia (ALL) patients and remains an essential drug in the treatment of ALL. Poor response to L-asparaginase is associated with increased risk of therapeutic failure in ALL. However
Kristina Heyne et al.
Cell cycle (Georgetown, Tex.), 12(15), 2479-2492 (2013-07-11)
The inflammation regulating transcription factor NFκB and the tumor-suppressing transcription factor p53 can act as functional antagonists. Chronic inflammation (NFκB activity) may contribute to the development of cancer through the inhibition of p53 function, while, conversely, p53 activity may dampen
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique